MedTrace Logo

Synvisc Injections for Lumbar Facet Joint Pain

NCT00325845 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2006-09-13

No results posted yet for this study

Summary

The objective of this investigation is to evaluate the safety and efficacy of viscosupplementation in treating symptomatic lumbar facet joint arthropathy. The intended use of the device (Synvisc) is to alleviate pain and improve function in patients with painful lumbar facet joint arthrosis by intra-articular injection into the involved joint.

Conditions

Interventions

PROCEDURE

Synvisc viscosupplementation

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    collaborator INDUSTRY

  • Virginia Commonwealth University

    collaborator OTHER

  • Sheltering Arms Physical Rehabilitation Hospitals

    lead OTHER

Principal Investigators

  • Michael J DePalma, MD · Sheltering Arms Physical Rehabilitation Hospitals; Virginia Commonwealth University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00325845 on ClinicalTrials.gov